Press Releases & Events 2019

All         |     2020     |     2019     |     2018     |     2017

State-of-the-art manufacturing facility will support clinical and commercial production of cell therapies for thousands of patients annually worldwide.

Tessa Therapeutics has established a new Scientific Advisory Board (SAB) with the appointment of a team of highly respected scientists, practicing clinicians and industry veterans.

Tessa Therapeutics today announced ‘proof-of-concept’ data from the preclinical study of TT16, a first-of-its-kind combination immunotherapy that integrates Chimeric Antigen Receptor (CAR) T cell therapy and oncolytic adenovirus expressing immunomodulatory molecules for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-positive solid tumors.

Mr Buchalter brings over thirty years’ experience in the biopharmaceutical industry, with strong corporate leadership and an extensive background in the commercial positioning and development of therapeutics in oncology.